Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1829 results
March 2025
-
Media Release
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Phase III study showed sustained proteinuria reduction at one… -
Media Release
New Novartis Phase III data demonstrate meaningful efficacy and safety results of intrathecal onasemnogene abeparvovec in broad patient population with SMA
New Novartis Phase III data demonstrate meaningful efficacy and safety results of intrathecal onasemnogene abeparvovec in broad patient population with SMA Treatment with investigational OAV101 IT… -
Media Release
Aktionäre von Novartis heissen an der Generalversammlung 2025 alle Anträge des Verwaltungsrats gut
Die Aktionärinnen und Aktionäre genehmigten die 28. Dividendenerhöhung in Folge. Für 2024 wird die Dividende auf CHF 3.50 (+6,1%) je Aktie erhöht, was einer Rendite von 3,5% entspricht1Die… -
Media Release
Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2025 Annual General Meeting
Shareholders approved 28th consecutive dividend increase to CHF 3.50 (+6.1%) per share for 2024, representing a 3.5% yield¹ Shareholders elected Giovanni Caforio as new member and Chair of the Board…
February 2025
-
Media Release
Novartis data presentations at AAAAI and AAD underscore commitment to advancing treatment of hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU)
Two-year efficacy and safety data analyses from Phase III SUNSHINE and SUNRISE trials of continuous Cosentyx® (secukinumab) treatment in HS to be presentedNew analyses of 52-week data from Phase III… -
Media Release
Novartis oral Fabhalta® (iptacopan) receives positive CHMP opinion for the treatment of adults living with C3 glomerulopathy (C3G)
If approved, Fabhalta® will be the only medicine indicated to selectively target the underlying cause of C3G1, an ultra-rare, progressive kidney disease with no currently approved treatments2-5… -
Story People and Culture
Parental leave – A leadership opportunity
At Novartis, we believe in the importance of balancing professional and personal responsibilities. This belief is embodied through our inclusive parental leave policy, which supports all our people in taking the time they need to be with their families during significant life events. To understand how this truly supports our colleagues we invited Sumeet, Global Head of Service Enablement & Governance, People Services & Solutions to share his story with us. -
Media Release
Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront
Anthos Therapeutics is a clinical-stage biopharmaceutical company developing abelacimab, a potential first-in-class monoclonal antibody targeting the FXI inhibition pathwayAbelacimab is currently in…
January 2025
-
Key Release
Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024
Ad hoc announcement pursuant to Art. 53 LRFull yearNet sales grew +12% (cc1, +11% USD) with core operating income1 up +22% (cc, +19% USD) Sales growth driven by continued strong performance from… -
Key Release
Novartis setzt die starke Umsatzdynamik mit Margenerhöhungen fort und erreicht 2024 wichtige Meilensteine bei Innovationen
Ad-hoc-Mitteilung gemäss Art. 53 KRGeschäftsjahrDer Nettoumsatz wuchs um +12% (kWk1, +11% USD), das operative Kernergebnis1 verbesserte sich um +22% (kWk, +19% USD)Das Umsatzwachstum… -
Pulse Update
Novartis presentation at J.P. Morgan Healthcare Conference 2025
-
Media Release
Novartis Entresto® US patent upheld by US Court of Appeals
Basel, January 13, 2025 – Novartis is pleased with the decision by the US Court of Appeals for the Federal Circuit (CAFC) that affirms the validity of the Entresto® (sacubitril/valsartan) combination…